[The Use of Rivaroxaban in Perioperative Period of Pulmonary Vein Antrum Isolation in Patients With Paroxysmal Atrial Fibrillation].
Results of an observational study. devoted to prevention of thromboembolic complications in patients with atrial fibrillation undergoing catheter pulmonary vein atrium isolation are discussed. Patients (n= 199) were divided into two comparable groups depending on the anticoagulant (rivaroxaban or warfarin) used. Clinical thromboembolic and/or hemorrhagic complications as well as rate of development of asymptomatic cerebral thromboembolisms in various periods after procedure were assessed. Main conclusion: rivaroxaban was not inferior to warfarin for thromboprophylaxis in patients with atrial fibrillation undergoing catheter pulmonary vein antrum isolation.
E A
EA
Belikov
K V
KV
Davtyan
O N
ON
Tkacheva
S A
SA
Boytsov
E P
EP
Mazygula
T N
TN
Shabanova
M S
MS
Molodtsov
M S
MS
Kharlap
S E
SE
Serdyuk
D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects; D001281:Atrial Fibrillation / Q000150:complications / Q000628:therapy; D017115:Catheter Ablation / Q000379:methods*; D016903:Drug Monitoring / Q000379:methods; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D008297:Male; D008875:Middle Aged; D009031:Moscow; D059035:Perioperative Period / Q000379:methods; D011667:Pulmonary Veins / Q000473:pathology / Q000601:surgery; D000069552:Rivaroxaban / Q000008:administration & dosage / Q000009:adverse effects; D013923:Thromboembolism / Q000209:etiology / Q000517:prevention & control; D016896:Treatment Outcome; D014859:Warfarin / Q000008:administration & dosage / Q000009:adverse effects
D000925:Anticoagulants; D014859:Warfarin; D000069552:Rivaroxaban